Top 10 Herbal Medicine Companies

Why the Herbal Medicine Market Is Growing at 13.32% CAGR

The Global Herbal Medicine Market was valued at USD 100.12 billion in 2024 and is projected to grow from USD 113.45 billion in 2025 to USD 396.18 billion by 2035, registering a CAGR of 13.32% during the forecast period (MRFR Report ID: MRFR/HC/3250-HCR, Analyst: Rahul Gotadki). Two structural forces underpin this exceptionally high CAGR — one rooted in culture and epidemiology, the other in technology and regulation.

On the demand side: the World Health Organization estimates that nearly 80% of the global population relies on traditional medicine for primary healthcare, a prevalence baseline that translates into a multi-hundred-billion-dollar existing consumption base that is now being formalized into commercially addressable market activity as product standardization, e-commerce distribution, and international regulatory harmonization bring previously informal herbal consumption into organized market channels.

The Asia-Pacific region dominates the global Herbal Medicine Market, accounting for 51.94% of the total and generating approximately USD 52 billion in revenue in 2024. This dominant position is attributed to the extensive adoption of Traditional Chinese Medicine (TCM), Ayurveda, Kampo (Japan) and various native herbal practices within the healthcare frameworks of nations such as China, India, Japan, South Korea and Southeast Asia. North America is the second-largest market, which is anticipated to reach USD 25.03 billion by 2025 owing to the health-conscious consumer culture, growing acceptance of integrative medicine, and significant e-commerce penetration.

Europe follows, led by Germany, UK, and France, where the EU Traditional Herbal Medicinal Products Directive (THMPD) provides a regulatory pathway that has elevated product quality standards and legitimized herbal medicine within the European pharmaceutical framework.

What Structurally Separates Herbal Medicine Market Leaders from the Field

MRFR identifies four structural axes defining category leadership in the Herbal Medicine Market: (1) Traditional medicine system ownership — companies whose brands are native to a major traditional medicine system (Himalaya in Ayurveda, Dabur in Ayurveda, Schwabe in European phytomedicine, Tsumura in Kampo) command an authenticity and heritage premium that supplement-only brands built on sourced ingredients cannot replicate; (2) Clinical validation depth — the Schwabe Group's investment in placebo-controlled clinical trials for flagship products (Tebonin for memory, Crataegutt for cardiac support) creates a phytopharmaceutical quality tier that commands pharmacy-channel distribution and physician recommendation in regulated markets.

Top 10 Global Herbal Medicine Companies — MRFR Rankings (2026)

Rankings reflect MRFR's qualitative assessment of scale, strategic position, and market influence in the herbal medicine sector. Revenue figures are drawn from official company filings where public; private company figures are clearly marked as third-party estimates.

Company Profiles

1. Herbalife Ltd | NYSE: HLF | Los Angeles, California, USA

Herbalife's competitive architecture is built on direct selling scale rather than pharmacy or retail shelf presence: a global network of approximately 4 million distributors creates consumer reach in 90+ countries through a personalized sales model that converts herbal nutrition into a relationship purchase rather than a commodity transaction. The company announced net sales of USD 4.99 billion for FY2024, beating its projection range despite a 1.4% decrease from FY2023, along with Adjusted EBITDA of USD 634.8 million.

Herbalife’s 2024 Restructuring Program is targeted to achieve USD 80 million of annual savings starting in 2025, as part of a purposeful cost base reconfiguration to protect margin in a volume-challenged customer environment. In September 2024, Herbalife got a Chinese regulatory license to sell a new plant-based herbal supplement, expanding its Asia-Pacific foothold into China’s fully regulated supplement category — a critical beachhead in the world’s largest herbal medicine consumption market.

2. Dabur India Ltd | NSE: DABUR | Ghaziabad, India

Dabur is India’s most trusted Ayurvedic brand with 140+ years of legacy and eight different Power Brands that have category leadership in Chyawanprash, Honey, oral care and hair oils. The company reported full-year FY2025 revenue of INR 12,563 Crore (~USD 1.5 billion), with its International Business delivering 17% constant-currency growth for the full year.

This performance underlines Dabur’s growing capacity to monetise the global Ayurveda trend beyond its Indian domestic base. Dabur’s stake buy in Capiva (June 2024) is a strategic investment in the premium herbal startup ecosystem, complementing its core mass-market brand architecture with equity exposure to the fast-growing direct-to-consumer Ayurvedic wellness niche. Dabur is present in 7.9 million retail outlets in India and exports to 100+ countries.

3. Himalaya Wellness Company | Private | Bangalore, India

Himalaya Wellness has systematically converted Ayurvedic tradition into scientific credibility: the company's 290+ researchers have generated 1,200+ scientific studies supporting its portfolio, a clinical validation depth that positions Himalaya not as a traditional herbal brand competing on heritage alone but as an evidence-supported alternative to synthetic pharmaceuticals in hepatology, respiratory health, cardiac support, and dermatology.

Founded in 1930, Himalaya sells in 106 countries through integrated pharmaceutical, personal care, baby care, nutrition, and animal health product verticals, with its flagship Liv.52 hepatic protective formulation having been commercially available since 1955 — among the world's longest-tenured herbal pharmaceutical products.

4. Dr. Willmar Schwabe GmbH & Co. KG | Private | Karlsruhe, Germany

The Schwabe Group represents the gold standard of European phytomedicine: a 160-year heritage of clinical herbal pharmaceutical development that has produced the world's most rigorously studied plant-based medicines, including Tebonin (ginkgo biloba for memory and circulation), Crataegutt (hawthorn for cardiac function), and Venoplant (horse chestnut for venous insufficiency).

Unlike consumer supplement herbal brands, Schwabe's flagship products are supported by placebo-controlled clinical trials and registered as medicines under the EU THMPD framework. This regulatory status enables physician prescription, pharmacy-only distribution, and reimbursement eligibility in markets that distinguish between food supplements and medicinal herbal products.

5. Traditional Medicinals | Private (Employee-Owned) | Sebastopol, California, USA

Traditional Medicinals has built the largest retail herbal tea brand in North America on a model of botanical authenticity and supply chain integrity: the company sources directly from smallholder and cooperative herbal growers globally, maintains Fair Trade and organic certifications across its ingredient portfolio, and formulates products based on traditional use evidence combined with phytochemical standardization.

Employee-owned and B Corp certified, the company's governance model creates alignment between quality standards and long-term business sustainability that shareholder-driven competitors optimize away. The May 2024 opening of a new state-of-the-art manufacturing facility in Oregon — reflecting investment in production capacity to meet accelerating demand — signals that Traditional Medicinals is scaling its production infrastructure to match growth in the mainstream grocery and health retail channels. The company holds an estimated 4.2% global natural medicine market share.

6. Gaia Herbs | Private (Majority-Owned by Roquette) | Brevard, North Carolina, USA

Gaia Herbs' competitive differentiation is its farm-to-bottle traceability model — enabled by the company's 350-acre certified organic farm in North Carolina, which provides vertically integrated control over cultivation, harvest timing, and phytochemical quality from the agricultural source through to finished product.

This supply chain integration is not merely a marketing claim: Gaia's proprietary Purity-Tested label provides consumers with QR-code access to third-party test results for every batch, creating a transparency standard that outsourced-ingredient competitors cannot match without equivalent agricultural investment. In April 2024, the company appointed a new CEO to accelerate its expansion phase, signaling its intent to move beyond its premium specialty retail base into broader distribution.

7. Nature's Way | Subsidiary of Schwabe Group | Green Bay, Wisconsin, USA

Nature's Way is the Schwabe Group's North American mass-market vehicle — bringing German phytomedicine heritage into US grocery, pharmacy, and now e-commerce channels at accessible price points with broad SKU coverage across virtually every major herbal ingredient category.

The company's August 2024 exclusive Amazon partnership to launch a herbal immunity product line is a strategic signal that traditional herbal brands are deploying e-commerce exclusivity arrangements to capture the rapidly growing online supplement consumer without cannibalizing existing retail relationships. The February 2024 acquisition of a vertically integrated turmeric farm in India positions Nature's Way for the curcumin supply security that its best-selling Turmeric/Curcumin franchise requires — directly addressing ingredient quality vulnerability that contract-sourced competitors face in volatile commodity spice markets.

8. Bioforce AG (A.Vogel) | Private | Roggwil, Switzerland

Bioforce's competitive differentiation within the European herbal market is its exclusive focus on fresh herb preparations rather than dried herb extracts — a processing distinction that the company's founder, Alfred Vogel, embedded as a core scientific premise in 1963, arguing that fresh plant extraction preserves a broader spectrum of bioactive phytochemical constituents than the drying and milling processes used by conventional herbal manufacturers.

The A.Vogel brand's Echinaforce (fresh Echinacea purpurea extract) has become one of the most clinically studied herbal immune products in Europe, with multiple randomized controlled trials supporting its efficacy — enabling Bioforce to claim evidence-backed differentiation from the commodity echinacea supplement market.

9. Blackmores Limited | Acquired by Kirin Holdings | Sydney, Australia

Blackmores' February 2023 acquisition by Japan's Kirin Holdings for AUD 1.88 billion — the largest takeover in Australian natural health history — repositioned the 90-year-old Australian supplement brand as the anchor of a Japanese-led Asia-Pacific natural health platform. Under Kirin ownership, Blackmores now has access to Japanese distribution infrastructure, R&D resources, and consumer branding capabilities that accelerate its Southeast Asian and China expansion strategies beyond what a standalone Australian-listed company could fund.

10. Zandu Pharmaceutical Works / Emami Ltd | NSE: EMAMILTD | Kolkata, India

Zandu is one of India's oldest and most recognized Ayurvedic OTC brands — with products like Zandu Balm (pain relief), Zandu Pancharishta (digestive tonic), and Zandu Chyawanprash (immunity supplement) embedded in Indian consumer households across generations. Acquired by Emami Ltd in 2008, Zandu now operates as a flagship brand within Emami's eight-brand power portfolio, contributing Ayurvedic pharmaceutical heritage to an FMCG group that reported consolidated revenue of approximately INR 3,737 Crore (approximately USD 450 million) for FY2024.

M&A Activity Tracker

R&D & Innovation Signals

• Schwabe Group's Phyto Innovation Challenge — an open innovation fund of approximately EUR 1 million supporting universities and startups developing new herbal medicine solutions — represents the leading model for pharmaceutical-quality herbal R&D collaboration, connecting European phytomedicine expertise with academic botanical science and digital health startup innovation in a funding framework that competitors are beginning to replicate.

• Himalaya Wellness's Ayurvedic pharmacology center (established July 2023 in partnership with a leading Indian research institute) is the most significant institutional herbal clinical validation investment in the Indian market, focused specifically on generating clinical trial data that meets global regulatory standards — enabling Himalaya to convert its Ayurvedic heritage portfolio into evidence-backed pharmaceutical submissions in the EU, US, and Middle Eastern markets.

• Gaia Herbs' regenerative agriculture training center (opened November 2023) addresses the supply chain R&D dimension of herbal medicine innovation: ensuring sustainable cultivation of medicinal plants whose wild-harvest populations are under pressure from rising global demand, and training contract farmers in phytochemical quality management practices that directly determine finished product consistency.

• EMA's May 2025 marketing authorization for Hanmi Pharmaceutical's HMPL-523 herbal Alzheimer's treatment marks the frontier advance of herbal pharmaceutical clinical development — demonstrating that plant-derived medicines can complete Phase III randomized controlled trial programs and obtain full European regulatory authorization for a high-stakes neurological indication. This precedent will accelerate similar development programs across the TCM and Korean traditional medicine sectors.

• Nature's Way's vertically integrated turmeric farm acquisition in India (February 2024) is a supply-chain innovation investment targeting phytochemical standardization. By owning cultivation and primary processing, Nature's Way can specify curcuminoid content at the agricultural source, producing curcumin extract with batch-to-batch consistency that commodity-sourced competitors relying on spot market ingredient procurement cannot guarantee.